Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Change in Receivables: 2020-2025

Historic Change in Receivables for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $703,000.

  • Xeris Biopharma Holdings' Change in Receivables rose 153.99% to $703,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $12.6 million, marking a year-over-year increase of 361.25%. This contributed to the annual value of $1.2 million for FY2024, which is 85.44% down from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Change in Receivables stood at $703,000 for Q3 2025, which was down 89.54% from $6.7 million recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Change in Receivables peaked at $15.7 million during Q3 2023, and registered a low of -$6.8 million during Q4 2023.
  • In the last 3 years, Xeris Biopharma Holdings' Change in Receivables had a median value of $30,000 in 2023 and averaged $2.1 million.
  • Data for Xeris Biopharma Holdings' Change in Receivables shows a peak YoY increase of 891.50% (in 2024) and a maximum YoY decrease of 6,043.33% (in 2024) over the last 5 years.
  • Xeris Biopharma Holdings' Change in Receivables (Quarterly) stood at -$449,000 in 2021, then soared by 837.64% to $3.3 million in 2022, then crashed by 304.38% to -$6.8 million in 2023, then surged by 89.32% to -$723,000 in 2024, then surged by 153.99% to $703,000 in 2025.
  • Its Change in Receivables was $703,000 in Q3 2025, compared to $6.7 million in Q2 2025 and $5.9 million in Q1 2025.